Durvalumab
- Generic Name
- Durvalumab
- Brand Names
- Imfinzi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1428935-60-7
- Unique Ingredient Identifier
- 28X28X9OKV
- Background
Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tum...
- Indication
Durvalumab is indicated for the treatment of adults with the following conditions:
- Associated Conditions
- Extensive-stage Small Cell Lung Cancer (SCLC), Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer, Metastatic Non-Small Cell Lung Cancer, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Stage III Non-small Cell Lung Cancer, Unresectable, locally advanced PD-L1 positive Lung Cancer Non-Small Cell Cancer (NSCLC)
- Associated Therapies
- First Line Chemotherapy
Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab
- Conditions
- Interventions
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2022-10-05
- Lead Sponsor
- Fondazione Ricerca Traslazionale
- Target Recruit Count
- 176
- Registration Number
- NCT05568212
- Locations
- 🇮🇹
Istituti Fisioterapici Ospitalieri- Ifo - Istituto Regina Elena, Roma, RM, Italy
Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma
- First Posted Date
- 2022-09-28
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 210
- Registration Number
- NCT05557838
- Locations
- 🇨🇳
Research Site, Zhengzhou, China
A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours
- Conditions
- Interventions
- First Posted Date
- 2022-08-24
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14
- Registration Number
- NCT05514132
- Locations
- 🇨🇳
Research Site, Shandong, China
Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases
- Conditions
- Interventions
- First Posted Date
- 2022-08-02
- Last Posted Date
- 2022-08-05
- Target Recruit Count
- 58
- Registration Number
- NCT05484583
Combining ICI With SBRT or HypoFrx-RT for ES NSCLC
- Conditions
- Interventions
- First Posted Date
- 2022-07-11
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Alexander Chi
- Target Recruit Count
- 83
- Registration Number
- NCT05451173
- Locations
- 🇨🇳
Capital Medical University Xuanwu Hospital, Beijing, Beijing, China
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2022-07-11
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 594
- Registration Number
- NCT05450692
- Locations
- 🇬🇧
Research Site, Wirral, United Kingdom
Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment with PACIFIC Regimen
- Conditions
- Interventions
- First Posted Date
- 2022-07-05
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 11
- Registration Number
- NCT05443971
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-06-09
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 18
- Registration Number
- NCT05411094
- Locations
- 🇺🇸
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison, Wisconsin, United States
🇺🇸UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
🇺🇸Los Angeles General Medical Center, Los Angeles, California, United States
Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-05-24
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 33
- Registration Number
- NCT05388006
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
......SMARTEST Trial......
- Conditions
- Interventions
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 30
- Registration Number
- NCT05380713
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.